Evolving Treatments in Hepatocellular Carcinoma: Updates from ASCO GI 2024 : Episode 10

Opinion

Video

March 25, 2024

IMBrave150 Study Overview

Dr Gong breaks down the structure and key takeaways from the IMBrave150 study.

EP: 1.Hepatocellular Carcinoma (HCC) Disease State Overview

EP: 2.Utilizing Interventional Radiology and Liver-directed Therapies

EP: 3.Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC

EP: 4.EMERALD-1 Study: Significance as Presented at ASCO GI 2024

EP: 5.EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies

EP: 6.IMBrave-050 Study Overview

EP: 7.Patient Profile 1: Advanced HCC Treated with Durvalumab and Tremelimumab

EP: 8.HIMALAYA Study in Advanced Stage HCC

EP: 9.Establishing Optimal HCC Treatment Strategy

EP: 10.IMBrave150 Study Overview

EP: 11.HCC Treatment Strategy Driven by Real-World Evidence

EP: 12.Combining Liver-directed and Systemic Therapies in HCC

EP: 13.Patient Profile 2: Patient Progression After Frontline HCC Therapy

EP: 14.CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape

EP: 15.REGONEXT Study: Driving Second-line HCC Treatment Strategy

EP: 16.Trajectory of Evolving HCC Treatment Landscape

Related Videos

Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center

Richard Kim, MD, Moffitt Cancer Center

Related Content

Squamous cell anal carcinoma | Image Credit: © Anatomy Insider - stock.adobe.com

December 20th 2024

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising

OncLive On Air

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA

December 18th 2024

FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Michael J. Pishvaian, MD, PhD, director, Gastrointestinal, Developmental Therapeutics and Clinical Research Programs, associate professor of Oncology, Johns Hopkins Medicine

December 13th 2024

Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management

FDA

December 4th 2024

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma

Related Content

Squamous cell anal carcinoma | Image Credit: © Anatomy Insider - stock.adobe.com

December 20th 2024

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising

OncLive On Air

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA

December 18th 2024

FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Michael J. Pishvaian, MD, PhD, director, Gastrointestinal, Developmental Therapeutics and Clinical Research Programs, associate professor of Oncology, Johns Hopkins Medicine

December 13th 2024

Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management

FDA

December 4th 2024

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma

Latest Conference Coverage

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.